Maynard Um
-
-
-
-
-
-
-
Leerink Upgrades Halozyme Therapeutics (HALO) to Outperform
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Reiterated at Market Outperform by Citizens on Beating Q1 Estimates
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Q4 Results
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised at TD Cowen; 'One of Our Top Picks for 2026'
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $92 at Citizens on Strong Quarter
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance
-
466,298 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


